Status:
COMPLETED
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 2 diabetes mellitus. The study will be conducted in participants with type 2 diabetes on insuli...
Eligibility Criteria
Inclusion
- Are male or female participants with Type 2 Diabetes Mellitus (T2DM) for at least 1 year
- Have a body mass index (BMI) of 18.5 to 35.0 kilogram per meter square (kg/m²)
- Have a glycated hemoglobin (HbA1c) less than (\<)9.0 percent (%)
- Have had no episodes of severe hypoglycaemia in the last 6 months
Exclusion
- Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T2DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
- Have a history of renal impairment
- Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives
- Have proliferative retinopathy or maculopathy and/or severe neuropathy
Key Trial Info
Start Date :
October 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2017
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03305822
Start Date
October 11 2017
End Date
December 14 2017
Last Update
May 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Neuss, North Rhine-Westphalia, Germany